Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 3/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006673 | 1.00 | HDAC1 (0.54) | HDAC1HDAC8MAOBF2USP2 | |
| SCHEMBL14820597 | 0.88 | HDAC1 (0.71) | HDAC1HDAC8MAOBF2USP2 | |
| SCHEMBL1607899 | 0.86 | NLRP3 (0.53) | KDM4EALDH1A1ENPP2CA2CYP2A6 | |
| SCHEMBL30006017 | 0.86 | NLRP3 (0.53) | KDM4EALDH1A1ENPP2CA2CYP2A6 | |
| SCHEMBL29518264 | 0.84 | MAPT (0.56) | HDAC1HDAC8MAOBUSP2GAA | |
| SCHEMBL3400912 | 0.84 | MAPT (0.56) | HDAC1HDAC8MAOBUSP2GAA | |
| SCHEMBL6844115 | 0.83 | HDAC1 (0.55) | HDAC1HDAC8MAOBF2USP2 | |
| SCHEMBL1230497 | 0.80 | HDAC1 (0.48) | HDAC1HDAC8MAOBF2USP2 | |
| SCHEMBL8990474 | 0.79 | HDAC1 (0.60) | HDAC1HDAC8MAOBUSP2GAA | |
| SCHEMBL9097010 | 0.79 | HDAC1 (0.50) | HDAC1HDAC8MAOBUSP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101983059-B | New 2,3,4,5-terahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES INC | 2014-11-05 | — | — | CN | claimed |
| EP-0035474-B1 | AMIDINES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | claimed |
| US-20230116201-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4139291-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4097084-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021154902-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-0666258-A1 | Indolylcycloaklanylamin- und Indolylcycloalkenylamine derivatives, their preparation and their use as anti-migraine agents | Bristol-Myers Squibb Company (US) | 1995-08-09 | — | — | EP | disclosed |
| US-5416066-A | FOR THE PREVENTION OF MYOCARDIAL INFARCTION OR INHIBITING MYOCARDIAL NECROSIS | KIRIN BREWERY CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0565721-A1 | 1,4-BENZOTHIAZEPINE DERIVATIVE | KANEKO, Noboru (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-4650810-A | OR INDOLE-5-THIOACETAMIDES | GLAXO GROUP LIMITED (GB) | 1987-03-17 | — | — | US | disclosed |
| US-4650810-A | OR INDOLE-5-THIOACETAMIDES | GLAXO GROUP LIMITED (GB) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116201-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | HDAC1 1204/4885HDAC8 2830/4885MAOB 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.